SCHEMBL29759451

SCHEMBL29759451

O=C(O)c1cc(F)ccc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 4/20 0.66
CA1 P00915 3/20 0.66
CA2 P00918 3/20 0.66
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
KDM4E B2RXH2 2/20 0.66
ALDH1A1 P00352 2/20 0.66
HPGD P15428 2/20 0.66
HIF1A Q16665 2/20 0.66
HSD17B10 Q99714 2/20 0.66
DHFR P00374 2/20 0.66
USP2 O75604 1/20 0.66
LMNA P02545 1/20 0.66
TTR P02766 1/20 0.66
ALB P02768 1/20 0.66
HMGB1 P09429 1/20 0.66
CXCL12 P48061 1/20 0.66
SLC22A6 Q4U2R8 1/20 0.66
PTGS2 P35354 2/20 0.61
CA12 O43570 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130520 1.00 ACMSD (0.66) ACMSDCA1CA2MEN1KMT2A
SCHEMBL27405095 0.98 ACMSD (0.64) ACMSDCA1CA2MEN1KMT2A
Phosphoric Acid SCHEMBL31026334 0.92 ACMSD (0.58) ACMSDCA1CA2MEN1KMT2A
Phosphoric Acid SCHEMBL8776062 0.92 ACMSD (0.58) ACMSDCA1CA2MEN1KMT2A
Phosphoric Acid SCHEMBL31026333 0.92 ACMSD (0.58) ACMSDCA1CA2MEN1KMT2A
SCHEMBL27382597 0.87 MEN1 (0.54) ACMSDCA1CA2MEN1KMT2A
SCHEMBL330405 0.84 ACMSD (0.72) ACMSDCA1CA2MEN1KMT2A
SCHEMBL3695268 0.82 ACMSD (0.70) ACMSDCA1CA2MEN1KMT2A
SCHEMBL3690106 0.82 ACMSD (0.70) ACMSDCA1CA2MEN1KMT2A
SCHEMBL188203 0.82 ALDH1A1 (0.61) ACMSDCA1CA2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP disclosed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO disclosed
EP-4337203-A1 INHIBITORS OF THE MENIN-MLL INTERACTION Syndax Pharmaceuticals, Inc. (US) 2024-03-20 EP disclosed
EP-3541368-B1 IMAGEABLE PARTICLES, METHODS OF MAKING AND METHODS OF USE THEREOF US HEALTH (US) 2023-07-12 EP disclosed
WO-2022241265-A1 INHIBITORS OF THE MENIN-MLL INTERACTION SYNDAX PHARMACEUTICALS, INC. (US) 2022-11-17 WO disclosed
US-11382990-B2 Imageable polymers, methods of making and methods of use thereof THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11382990-B2 Imageable polymers, methods of making and methods of use thereof PUF60, PBRM1, PCBP1 ACMSD 1364/4885CA1 553/4885CA2 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.